- Home
- SDST vs NRSN Comparison
SDST vs NRSN Comparison
Compare SDST & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SDST | NRSN |
|---|---|---|
| Founded | 2022 | 2017 |
| Country | United States | Israel |
| Employees | 10 | 16 |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.0M | 26.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SDST | NRSN |
|---|---|---|
| Price | $2.49 | $0.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 151.0K | 117.4K |
| Earning Date | 05-14-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $583.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.14 | $0.63 |
| 52 Week High | $7.67 | $2.60 |
Technical Indicators
Market Signals| Indicator | SDST | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 41.45 | 55.90 |
| Support Level | $2.12 | $0.67 |
| Resistance Level | $3.00 | $0.86 |
| Average True Range (ATR) | 0.28 | 0.05 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 4.17 | 60.94 |
Price Performance
Historical ComparisonAbout SDST Stardust Power Inc.
Stardust Power Inc is developing a lithium refinery at its Facility in Muskogee, Oklahoma, with planned capacity of producing up to 50,000 metric tons per annum of BGLC once fully operational. The company will source lithium brine feedstock from various suppliers and may make investments upstream to secure additional feedstock. The Company seeks to sell its products to electric vehicle (EV) manufacturers as the primary market, with potential applications in other areas such as battery manufacturers, the U.S. military, and original equipment manufacturers (OEMs).
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.